Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on 'Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017'

Autor:	Derya Bocuk, Stefan Wohlfeil, Massoud Toussi, Birgit Ehlken, Annegret Gohlke, Lennart Nathell
Rok vydání:	2019
Předmět:	Pharmacology medicine.medical_specialty business.industry Pharmacology toxicology medicine Pharmacology (medical) Toxicology Intensive care medicine business FERRIC CARBOXYMALTOSE
Zdroj:	Drug Safety. 42:693-696
ISSN:	1179-1942 0114-5916
DOI:	10.1007/s40264-019-00815-4
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6d5e6a7c350b5be743b978d04d17c6cf https://doi.org/10.1007/s40264-019-00815-4 Zobrazit plný text záznamu Full text from SpringerLink